TerminatedPHASE1, PHASE2NCT03119064

BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma

Studying Glioblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Brown University
Principal Investigator
Howard Safran, MD
BrUOG Study Chair
Intervention
Nanoliposomal Irinotecan(drug)
Enrollment
12 enrolled
Eligibility
18 years · All sexes
Timeline
20172021

Study locations (1)

Collaborators

Merrimack Pharmaceuticals · Rhode Island Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03119064 on ClinicalTrials.gov

Other trials for Glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Glioblastoma

← Back to all trials